Home
Resources
Publications
The Phenanthrene Derivative PJ34 Exclusively Eradicates Human Pancreatic Cancer Cells in Xenografts

The Phenanthrene Derivative PJ34 Exclusively Eradicates Human Pancreatic Cancer Cells in Xenografts

Leonid Visochek, Dikla Atias, Itay Spektor, Asher Castiel, Talia Golan, Malka Cohen-Armon

Oncotarget. 2019 Oct 22;10(58):6269-6282.

PMID: 31692907

Abstract:

Recent reports demonstrate an exclusive eradication of a variety of human cancer cells by the modified phenanthridine PJ34. Their eradication during mitosis is attributed to PJ34 preventing NuMA clustering in the mitotic spindle poles of human malignant cells, which is crucial for their normal mitosis. Here, the effect of PJ34 is tested in cell cultures and xenografts of human pancreas ductal adenocarcinoma. Evidence is presented for a substantial reduction (80-90%) of PANC1 cancer cells in xenografts, measured 30 days after the treatment with PJ34 has been terminated. Benign cells infiltrated into the PANC1 tumors (stroma) were not affected. Growth, weight gain and behavior of the treated nude mice were not impaired during, and 30 days after the treatment with PJ34. The efficient eradication of malignant cells in human pancreas cancer xenografts presents a new model of pancreas cancer treatment.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP229878	Phenanthridine		229-87-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: